A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma - Berenson, J R; Matous, J; Swift, R A; Mapes, R; Morrison, B; Yeh, H S (Clin Cancer Res, 2007)